{
  "paper_id": "PMC5881609",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881609/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "DNA sources for MRD detection in hematologic malignancies. Graphic overview of distinct DNA sources for molecular disease profiling in hematologic neoplasms, which include circulating tumor DNA as part of the circulating cell-free DNA pool and circulating tumor cells in the bloodstream as well as malignant cells in the BM compartment. Their main characteristics and role in hematologic cancers are displayed in the table next to the graphic.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/26908440eb6e/blood735639f1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/26908440eb6e/blood735639f1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/26908440eb6e/blood735639f1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/26908440eb6e/blood735639f1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/26908440eb6e/blood735639f1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5881609/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/26908440eb6e/blood735639f1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Detection limits of methods used for DNA identification in PB and BM. Diagrams depicting the range of detection of methods used for identification of cellular DNA in PB and BM (A) and cell-free DNA in plasma (B). PB input material for each assay was considered from a normal 10 mL EDTA vacutainer. aAnalytical sensitivity highly depends on panel width, sequencing depth, and technical conditions (eg, barcoding, duplex sequencing). bAnalytical sensitivity substantially varies depending on the target/targets interrogated and number of input genomes. cAnalytical sensitivity depends on the method used and number of markers tested. WES, whole exome sequencing; WGS, whole genome sequencing.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/c15700a5b9f1/blood735639f2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/c15700a5b9f1/blood735639f2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/c15700a5b9f1/blood735639f2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/c15700a5b9f1/blood735639f2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/c15700a5b9f1/blood735639f2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5881609/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb16/5881609/c15700a5b9f1/blood735639f2.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Clinical impact of noninvasive disease detection at distinct disease milestones in myeloid malignancies\n\n\nDiagnosis\nPrecancerous condition\nDiagnosis/pretreatment\nDuring therapy\nPosttreatment/surveillance\nRelapse/progression\n\n\n\nAML\nHealthy PBMC: harbor age-dependent aberrations associated with overt AML/MDS138-142\n\nCTC or malignant BM cell: genotyping defines molecular prognostic factors150,151; genotyping might identify therapeutic targets (eg, FLT3)151,152\n\nCTC or malignant BM cell: positivity and kinetics during therapy predict risk of relapse155,157\n\nCTC or malignant BM cell: positivity postinduction and postconsolidation predicts clinical outcome156,157,161,164\n\nCTC or malignant BM cell: profiling identifies emergent clones at relapse163; profiling identifies relapse161\n\n\n\nCML\n\n\nCTC or malignant BM cell: BCR-ABL1 levels predict clinical outcome168-170; profiling identifies resistance mutations176,177,180,181\n\n\nCTC or malignant BM cell: rising BCR-ABL1 levels indicate progression178\n\n\n\nMPN\n\nCTC or malignant BM cell: genotyping is part of diagnostic criteria189\n\n\nCTC or malignant BM cell: levels predict clinical outcome190,191\n\n\n\n\n\nOpen in a new tab\nRole of PBMC, CTC, ctDNA, and BM cell profiling for detection of premalignant states in healthy individuals, identification of clinically relevant biomarkers, and prediction of outcome in myeloid malignancies at distinct disease milestones.Figure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "WES, whole exome sequencing; WGS, whole genome sequencing.In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Here, circulating tumor DNA (ctDNA) in the bloodstream can be used for noninvasive tumor detection (Tables 1 and 2; Figure 1).1,2 Unfortunately, the fraction of CTCs and ctDNA in the pool of normal PB mononuclear cells (PBMCs) or cell-free DNA is often very small.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "For example, a single gene test can only achieve a sensitivity of 1 in 20 000 if the input material matches or exceeds this threshold (Figure 2).5.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In hematologic neoplasms, several technologies have been established for noninvasive minimal residual disease (MRD) detection and response assessment: flow cytometry (eg, multicolor flow cytometry [MFC]), polymerase chain reaction (PCR)-based methods that do not rely on sequencing (quantitative real-time PCR [qPCR], digital PCR [dPCR], reverse transcription PCR [RT-PCR]), and high-throughput sequencing (HTS, next-generation sequencing [NGS]) methods, which allow massive parallel sequencing of DNA molecules in a single flow cell and produce millions or billions of sequences concurrently (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Key characteristics of methods used for noninvasive disease detection in hematologic malignancies\n\nOpen in a new tab\n\nColors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Colors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Colors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Colors in column 1 refer to the colors in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "These targeting methods include amplicon-based or targeted hybrid-capture techniques to select and enrich the genomic regions of interest.15-18 The ability to simultaneously detect and monitor multiple aberrations and recent methodological advances in reducing errors have improved analytical sensitivity of targeted HTS assays down to ∼0.0001% (Figure 2).16,19,20 Furthermore, HTS-based assays facilitate assessment of intra- and intertumor heterogeneity, allowing individualized detection of clonal evolution.21,22 Although HTS methods are becoming more common, they are not widely used in clinical laboratories yet and therefore are not prominently featured in disease management guidelines.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At AML diagnosis, profiling of certain gene rearrangements (eg, PML-RARA, CBFB-MYH11, RUNX1-RUNX1T1, BRC-ABL1) and mutations (eg, NPM1, FLT3-ITD, RUNX1, CEBPA) in BM or PB has become increasingly relevant for patient risk assessment and therapeutic decision-making.150-155 In addition, achieving deep CR without MRD is of key importance for assessment of clinical outcomes.155-157 MFC- and PCR-based technologies allow a highly sensitive (0.1%-0.001%), objective, and standardized assessment of treatment response over time (Figure 2A; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "However, they have several decisive advantages over conventional approaches such as MFC and PCR-based assays, at least for selected applications (Figure 2; Table 3).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 83,
    "images_downloaded": 2,
    "tables_filtered": 5
  }
}